Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia

Autor: Anders Själander, Johan Lanng Nielsen, Henrik Hjorth-Hansen, Satu Mustjoki, Kari Remes, Hans Ehrencrona, Ole Weiss Bjerrum, Anders Almqvist, Mats Björeman, Berit Markevärn, Fredrik Sandin, Franz Gruber, Kristina Myhr-Eriksson, Claes Malm, Max Flogegard, Arnon Nagler, V Kairisto, Ulla Strömberg, Perttu Koskenvesa, Anders Lindblom, Kimmo Porkka, Karin Olsson, Marjatta Sinisalo, Jesper Stentoft, Tobias Gedde-Dahl, Bengt Simonsson, Lotta Ohm, Anu Räsänen

Publikováno v: Simonsson, B, Gedde-Dahl, T, Markevärn, B, Remes, K, Stentoft, J, Almqvist, A, Björeman, M, Flogegård, M, Koskenvesa, P, Lindblom, A, Malm, C, Mustjoki, S, Myhr-Eriksson, K, Ohm, L, Räsänen, A, Sinisalo, M, Själander, A, Strömberg, U, Bjerrum, O W, Ehrencrona, H, Gruber, F, Kairisto, V, Olsson, K, Sandin, F, Nagler, A, Nielsen, J L, Hjorth-Hansen, H, Porkka, K & Nordic CML Study Group 2011, ' Combination of pegylated IFN-α2b with imatinib increases molecular response rates in patients with low-or intermediate-risk chronic myeloid leukemia ', Ironic Blood, vol. 118, no. 12, pp. 3228-35 . https://doi.org/10.1182/blood-2011-02-336685

Biologic and clinical observations suggest that combining imatinib with IFN-α may improve treatment outcome in chronic myeloid leukemia (CML). We randomized newly diagnosed chronic-phase CML patients with a low or intermediate Sokal risk score and i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9674851dfcdb18ca880ccd2a0c5a7e59
https://doi.org/10.1182/blood-2011-02-336685

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Autor: Leif Stenke, Arta Dreimane, Bengt Simonsson, Ulla Olsson-Strömberg, Claes Malm, Mats Björeman, Karin Hellström, Lotta Ohm, Hans Wadenvik, Berit Markevärn, Fredrik Sandin, Magnus Björkholm, Kristina Myhr-Eriksson, Sören Lehmann, Martin Höglund, Marja Ekblom, Anders Själander, Johan Richter, Mats Brune, Per Ljungman

Publikováno v: Blood. 122(7)

Clinical management guidelines on malignant disorders are generally based on data from clinical trials with selected patient cohorts. In Sweden, more than 95% of all patients diagnosed with chronic myeloid leukemia (CML) are reported to the national

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ed652560f17da59bd2b07b0634ebc417
https://pubmed.ncbi.nlm.nih.gov/23843494

Early Disease Relapse after Tyrosine Kinase Inhibitor Treatment Discontinuation in CML Is Related Both to Low Number and Impaired Function of NK-Cells

Autor: Hans Ehrencrona, Kourosh Lotfi, Leif Stenke, Anna Lübking, Satu Mustjoki, Johan Richter, Mette Ilander, Martin C. Müller, Kimmo Porkka, Claes Malm, Francois-Xavier Mahon, Berit Markevärn, Lotta Ohm, Susanne Saussele, Hanna Lähteenmäki, Martin Höglund, Anders Själander, Henrik Hjorth-Hansen, Mats Björeman, Stina Söderlund, Joelle Guilhot, Markus Pfirrmann, Waleed Majeed, Marja Ekblom, Elena Holm, Sören Lehmann, Perttu Koskenvesa, Kasanen Tiina, Ulla Olsson-Strömberg

Publikováno v: Blood. 124:812-812

Background: Recent reports suggest that approximately 40% of CML patients who have achieved sustained complete molecular remission are able to stop TKI treatment without disease relapse. However, there are no predictive markers for successful therapy

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::80c1726f2e4d4e615c452c6bae320e51
https://doi.org/10.1182/blood.v124.21.812.812

Effect of Time to Dasatinib Initiation On Outcome of Imatinib-Intolerant Patients with Chronic-Phase Chronic Myelogenous Leukemia (CP-CML): Results From a European Observational Study (FORTE; CA180–211)

Autor: Juan Luis Steegmann, Miranda Pans, David Marin, Marc van Baardewijk, Gregor Verhoef, Aloysius Ho, Gert J. Ossenkoppele, Mats Björeman, M. Lurdes Guerra, Mauricette Michallet, Ernst Schloegl, Andrzej Hellmann, Kajetana Foryciarz, Enrica Morra, Ave Mori, Kazimierz Kuliczkowski, Antonella Gozzini, Dietger Niederwieser

Publikováno v: Blood. 118:1689-1689

Abstract 1689 Background: Approximately half of patients with chronic-phase chronic myelogenous leukemia (CP-CML) fail imatinib treatment, both in interventional (Deininger et al., Blood 2009 114: abstract 1126) and observational trials (Michallet et

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1f42553a5dfff7f19d41c8bb38d5652
https://doi.org/10.1182/blood.v118.21.1689.1689

Intensive treatment in order to minimize the Ph-positive clone in chronic myelogenic leukemia

Autor: Ann-Mari Udén, Claes Malm, Bengt Simonsson, Robert Hast, Anders Wahlin, Gösta Gahrton, Gunnar Öberg, Jan Westin, Mats Björeman, Andreas Killander, Eva Löfvenberg, Jan Carneskog, Ingemar Turesson, Lars Vilén, Magnus Björkholm

Publikováno v: Leukemialymphoma.

Several studies indicate that interferon (IFN) treatment, intensive chemotherapy and autologous bone marrow transplantation (ABMT) effectively reduce the Ph-positive clone in Chronic Myelogenic Leukemia (CML). In the present study on patients ≤ 55

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c132a7d77ce3058e6b7f0283f7d5946d
https://pubmed.ncbi.nlm.nih.gov/1283548